Showing 21-30 of 56 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Transcriptional memory in human islet organogenesis | Lundquist Institute for Biomedical Medical Innovation at Harbor‐UCLA Medical Center (The Lundquist Institute) | Eiji Yoshihara | Cures | 01-April-2022 to 31-March-2027 | $749,995.50 |
| Preclinical evaluation of SERCA2 activators for pancreatic beta-cell protection in T1D | Neurodon LLC | Russell Dahl | Cures | 01-June-2022 to 31-May-2026 | $920,000.00 |
| GPR75, a novel actor in beta cell regeneration | New York Medical College | Ercument Dirice | Cures | 01-April-2022 to 31-March-2027 | $750,000.00 |
| Reducing Glycemic Variability to Improve Cardiovascular Health in Type 1 Diabetes | Rector & Visitors of the University of Virginia | William Horton | Improving Lives | 01-December-2022 to 30-June-2027 | $858,072.00 |
| Clinical Validation of a Smart Bolus Calculator Informed by Insulin Sensitivity in Adults and Adolescents with Type 1 Diabetes | Rector & Visitors of the University of Virginia | Chiara Fabris | Improving Lives | 01-June-2020 to 30-June-2027 | $604,390.26 |
| Antigenic Targets of CD4 T cells across the stages of type 1 diabetes | Regents of the University of Colorado | Maki Nakayama | Cures | 01-August-2022 to 31-July-2026 | $750,000.00 |
| Innovating Methods for AssessinG INsulin Action in Type ONe diabetes (IMAGINATiON) | Regents of the University of Colorado | Kristen Nadeau | Improving Lives | 01-December-2021 to 31-December-2026 | $445,816.29 |
| Islet autoantibody concordance and metabolic monitoring of individuals identified at risk for type 1 diabetes through population-based screening | Regents of the University of Colorado | Kimber Simmons | Cures | 01-July-2023 to 31-December-2026 | $750,000.00 |
| Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes | Regents of the University of Colorado | Jessica Kendrick | Improving Lives | 01-October-2022 to 30-September-2026 | $899,235.00 |
| EFFICACY AND SAFETY OF ONCE WEEKLY SEMAGLUTIDE IN ADULTS WITH OBESITY AND INADEQUATELY CONTROLLED TYPE 1 DIABETES USING HYBRID CLOSED-LOOP SYSTEM | Regents of the University of Colorado | Janet Snell-Bergeon | Improving Lives | 01-November-2022 to 31-October-2026 | $2,282,771.83 |